It's Showtime for National Research
National Research (NAS: NRCIB) is expected to report Q2 earnings on Aug. 6. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict National Research's revenues will expand 12.0% and EPS will contract 0.0%.
The average estimate for revenue is $23.1 million. On the bottom line, the average EPS estimate is $0.16.
Last quarter, National Research logged revenue of $24.9 million. GAAP reported sales were 11% higher than the prior-year quarter's $22.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
Last quarter, EPS came in at $0.18. GAAP EPS of $0.18 for Q1 were 13% higher than the prior-year quarter's $0.16 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the preceding quarter, gross margin was 58.9%, 120 basis points worse than the prior-year quarter. Operating margin was 29.0%, 190 basis points better than the prior-year quarter. Net margin was 17.9%, 70 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $97.5 million. The average EPS estimate is $0.69.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 113 members out of 119 rating the stock outperform, and six members rating it underperform. Among 39 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 37 give National Research a green thumbs-up, and two give it a red thumbs-down.
Is National Research the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add National Research to My Watchlist.
The article It's Showtime for National Research originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.